Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05386823 Terminated - Healthy Clinical Trials

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

Start date: March 27, 2021
Phase: Phase 1
Study type: Interventional

HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for the induction of remission in patients with acute promyelocytic leukemia (APL) and for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs). This phase 1 Trial is a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HF1K16.

NCT ID: NCT05254613 Terminated - Healthy Clinical Trials

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants

Start date: November 12, 2019
Phase: Phase 1
Study type: Interventional

This study will evaluate the effects of single ascending doses (SAD) and multiple ascending doses (MAD) of ALXN1830 administered subcutaneously (SC) to healthy adult participants.

NCT ID: NCT04941989 Terminated - Healthy Clinical Trials

A Study in Healthy Subjects to Assess the Safety, Tolerability and Pharmacokinetics of HTL0022562

Start date: June 22, 2021
Phase: Phase 1
Study type: Interventional

Phase 1, randomised, double-blind, first in human, two part, single centre, placebo controlled, single and multiple ascending dose trial in healthy adult subjects to evaluate the safety, tolerability and pharmacokinetics of HTL0022562.

NCT ID: NCT04811573 Terminated - Healthy Clinical Trials

A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food

Start date: March 31, 2021
Phase: Phase 1
Study type: Interventional

The aim of this trial is to establish bioequivalence between EU-, US- and Japan-sourced Otezla® tablet formulations to assure comparability of results from Phase III trials of BI 730357 (new oral agent for treatment of psoriasis as well as other T helper 17 cells (Th17)-mediated diseases) regardless of whether only the EU-sourced Otezla® or EU and US-sourced Otezla®/Japan-sourced Otezla® have been used as an active comparator.

NCT ID: NCT04730804 Terminated - Healthy Clinical Trials

A Study of ALXN1830 in Healthy Adult Participants

Start date: March 17, 2021
Phase: Phase 1
Study type: Interventional

This trial will study the effects of single and multiple doses of ALXN1830 in healthy adult participants.

NCT ID: NCT04575818 Terminated - Healthy Clinical Trials

A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Start date: September 16, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of GLPG4059 in healthy volunteers after single oral administrations of GLPG4059 (SAD), compared to placebo (part 1). The effect of food (FE) (high-fat, high calorie) on the pharmacokinetics and relative bioavailability (rBA) of GLPG4059 will be assessed (part 2).

NCT ID: NCT04566926 Terminated - Healthy Clinical Trials

A Study of JNJ-64140284 in Healthy Male Participants

AMPAR
Start date: September 29, 2020
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate and compare the pharmacokinetic (PK) profiles of a single dose of two solid dosage formulations of JNJ-64140284 in plasma and urine in healthy male participants under fed and fasting conditions; and to investigate the safety and tolerability of two solid dosage formulations of JNJ 64140284 versus placebo after single oral dose administration in healthy male participants under fed and fasting conditions in Part 1; to investigate the safety and tolerability of JNJ-64140284 versus placebo after single oral dose administration (or 1 divided dose, if applicable) (ascending dose levels) in healthy male participants; and to characterize the PK of a single dose (or 1 divided dose, if applicable) of JNJ-64140284 in plasma in healthy male participants in Part 2; and to investigate the effect of food on the PK of a single (or 1 divided dose, if applicable) therapeutic relevant dose of JNJ 64140284 in healthy male participants; and to investigate the safety and tolerability of JNJ-64140284 versus placebo after single oral dose administration at a therapeutic relevant dose (or 1 divided dose, if applicable) in fed conditions in Part 3.

NCT ID: NCT04556032 Terminated - Healthy Clinical Trials

Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women

Start date: September 9, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to assess the effects of ergothioneine at two doses, compared to placebo, on cognition, mood, and sleep in healthy adult men and women.

NCT ID: NCT04540874 Terminated - Healthy Clinical Trials

A Study in Healthy Japanese Men to Test How Different Doses of BI 894416 Are Tolerated

Start date: October 5, 2020
Phase: Phase 1
Study type: Interventional

The objective of this trial is to investigate the safety, tolerability and pharmacokinetics of BI 894416 in healthy Japanese male subjects.

NCT ID: NCT04473651 Terminated - Healthy Clinical Trials

Safety and Tolerability of Lu AG06479 in Healthy Young Men

Start date: July 9, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.